Epinephrine inhibits PI3Kα via the Hippo kinases

[1]  Jared L. Johnson,et al.  An atlas of substrate specificities for the human serine/threonine kinome , 2023, Nature.

[2]  Jared L. Johnson,et al.  Host protein kinases required for SARS-CoV-2 nucleocapsid phosphorylation and viral replication , 2022, Science Signaling.

[3]  M. White,et al.  TAZ inhibits glucocorticoid receptor and coordinates hepatic glucose homeostasis in normal physiological states , 2021, eLife.

[4]  Xianming Deng,et al.  Glycogen accumulation and phase separation drives liver tumor initiation , 2021, Cell.

[5]  D. Duncker,et al.  Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals? , 2021, Basic Research in Cardiology.

[6]  G. Lewis,et al.  Direct and indirect control of hepatic glucose production by insulin. , 2021, Cell metabolism.

[7]  T. Harris,et al.  Adipocyte lipolysis drives acute stress-induced insulin resistance , 2020, Scientific Reports.

[8]  L. Cantley,et al.  Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer , 2020, Nature Reviews Endocrinology.

[9]  Matthew S. Tremblay,et al.  Neratinib is an MST1 inhibitor and restores pancreatic β-cells in diabetes , 2019, Cell Death Discovery.

[10]  Jared L. Johnson,et al.  Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors , 2019, Science.

[11]  Wenhao Zhang,et al.  The Protein Phosphatase 1 Complex Is a Direct Target of AKT that Links Insulin Signaling to Hepatic Glycogen Deposition. , 2019, Cell reports.

[12]  Suyong Choi,et al.  The Specificity of EGF-Stimulated IQGAP1 Scaffold Towards the PI3K-Akt Pathway is Defined by the IQ3 motif , 2019, Scientific Reports.

[13]  M. Malagón,et al.  High-fat diet promotes adrenaline production by visceral adipocytes , 2019, European Journal of Nutrition.

[14]  C. Dani,et al.  Enhanced β-adrenergic signalling underlies an age-dependent beneficial metabolic effect of PI3K p110α inactivation in adipose tissue , 2019, Nature Communications.

[15]  Chad J. Miller,et al.  Comprehensive profiling of the STE20 kinase family defines features essential for selective substrate targeting and signaling output , 2019, PLoS biology.

[16]  G. Shulman,et al.  Mechanisms of Insulin Action and Insulin Resistance. , 2018, Physiological reviews.

[17]  J. Burke.  Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. , 2018, Molecular cell.

[18]  Jamey D. Young,et al.  Loss of hepatic AMP-activated protein kinase impedes the rate of glycogenolysis but not gluconeogenic fluxes in exercising mice , 2017, The Journal of Biological Chemistry.

[19]  J. Zalvide,et al.  The MST3/STK24 kinase mediates impaired fasting blood glucose after a high-fat diet , 2017, Diabetologia.

[20]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[21]  A. Toker,et al.  AKT/PKB Signaling: Navigating the Network , 2017, Cell.

[22]  N. Gray,et al.  Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration , 2016, Science Translational Medicine.

[23]  M. Czech,et al.  Map4k4 Signaling Nodes in Metabolic and Cardiovascular Diseases , 2016, Trends in Endocrinology & Metabolism.

[24]  P. Romanienko,et al.  A Vector with a Single Promoter for In Vitro Transcription and Mammalian Cell Expression of CRISPR gRNAs , 2016, PloS one.

[25]  Yongjin Xu,et al.  Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model. , 2016, Bioorganic & medicinal chemistry letters.

[26]  S. Steinbacher,et al.  The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326). , 2016, Journal of medicinal chemistry.

[27]  G. Halder,et al.  MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway , 2015, Nature Communications.

[28]  Jamey D. Young,et al.  Mass spectrometry-based microassay of (2)H and (13)C plasma glucose labeling to quantify liver metabolic fluxes in vivo. , 2015, American journal of physiology. Endocrinology and metabolism.

[29]  M. Czech,et al.  Inducible Deletion of Protein Kinase Map4k4 in Obese Mice Improves Insulin Sensitivity in Liver and Adipose Tissues , 2015, Molecular and Cellular Biology.

[30]  M. P. Dillon,et al.  Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors. , 2015, ACS medicinal chemistry letters.

[31]  Zoe Cournia,et al.  Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant , 2014, PLoS Comput. Biol..

[32]  J. Borén,et al.  Increased expression of STK25 leads to impaired glucose utilization and insulin sensitivity in mice challenged with a high‐fat diet , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  C. Buchanan,et al.  Enzyme activity effects of N-terminal His-tag attached to catalytic sub-unit of phosphoinositide-3-kinase , 2013, Bioscience reports.

[34]  Doriano Fabbro,et al.  Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. , 2013, Bioorganic & medicinal chemistry letters.

[35]  Kun-Liang Guan,et al.  Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. , 2013, Genes & development.

[36]  G. Stamp,et al.  RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms , 2013, Cell.

[37]  M. Schulze,et al.  Association of Common Genetic Variants in the MAP4K4 Locus with Prediabetic Traits in Humans , 2012, PloS one.

[38]  Xiang-Dong Fu,et al.  Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.

[39]  P. Vogt,et al.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase , 2011, Cell cycle.

[40]  Roger L. Williams,et al.  Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases , 2011, Oncogene.

[41]  Gregory Stephanopoulos,et al.  Measuring deuterium enrichment of glucose hydrogen atoms by gas chromatography/mass spectrometry. , 2011, Analytical chemistry.

[42]  J. Eriksson,et al.  Effects of adrenaline on whole-body glucose metabolism and insulin-mediated regulation of glycogen synthase and PKB phosphorylation in human skeletal muscle. , 2011, Metabolism: clinical and experimental.

[43]  Jeannie T. Lee,et al.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. , 2009, Cancer cell.

[44]  K. Kinzler,et al.  A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.

[45]  K. Petersen,et al.  Regulation of net hepatic glycogenolysis and gluconeogenesis by epinephrine in humans. , 2009, American journal of physiology. Endocrinology and metabolism.

[46]  G. Rewcastle,et al.  Functional differences between two classes of oncogenic mutation in the PIK3CA gene. , 2009, Biochemical and biophysical research communications.

[47]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[48]  A. Pocai,et al.  Regulation of energy substrate utilization and hepatic insulin sensitivity by phosphatidylcholine transfer protein/StarD2 , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  D. Wasserman,et al.  Glucose Metabolism In Vivo in Four Commonly Used Inbred Mouse Strains , 2008, Diabetes.

[50]  R. Copeland,et al.  Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase , 2008 .

[51]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[52]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[53]  F. Dela,et al.  Caffeine's impairment of insulin‐mediated glucose disposal cannot be solely attributed to adrenaline in humans , 2007, The Journal of physiology.

[54]  Yuval Inbar,et al.  Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.

[55]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[56]  E. Kinoshita,et al.  Phosphate-binding Tag, a New Tool to Visualize Phosphorylated Proteins*S , 2006, Molecular & Cellular Proteomics.

[57]  Xiaoqing Tang,et al.  An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARγ, adipogenesis, and insulin-responsive hexose transport , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[58]  O. McGuinness,et al.  Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. , 2006, Diabetes.

[59]  M. Girvin,et al.  Mechanism of Constitutive Phosphoinositide 3-Kinase Activation by Oncogenic Mutants of the p85 Regulatory Subunit* , 2005, Journal of Biological Chemistry.

[60]  Craig R Malloy,et al.  Impaired Tricarboxylic Acid Cycle Activity in Mouse Livers Lacking Cytosolic Phosphoenolpyruvate Carboxykinase* , 2004, Journal of Biological Chemistry.

[61]  Lewis C Cantley,et al.  A rapid method for determining protein kinase phosphorylation specificity , 2004, Nature Methods.

[62]  E. Beutler,et al.  The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Shian Wu,et al.  hippo Encodes a Ste-20 Family Protein Kinase that Restricts Cell Proliferation and Promotes Apoptosis in Conjunction with salvador and warts , 2003, Cell.

[64]  I. Hariharan,et al.  The Drosophila Mst Ortholog, hippo, Restricts Growth and Cell Proliferation and Promotes Apoptosis , 2003, Cell.

[65]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[66]  L. Goodyear,et al.  Contraction Regulation of Akt in Rat Skeletal Muscle* , 2002, The Journal of Biological Chemistry.

[67]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[68]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[69]  A M Graybiel,et al.  A family of cAMP-binding proteins that directly activate Rap1. , 1998, Science.

[70]  A. Wittinghofer,et al.  Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP , 1998, Nature.

[71]  K. Petersen,et al.  Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. , 1998, The Journal of clinical investigation.

[72]  S. Harrison,et al.  Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes , 1996, Nature Structural Biology.

[73]  D. James,et al.  Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. , 1985, The American journal of physiology.

[74]  D. Wilmore,et al.  Epinephrine acutely mediates skeletal muscle insulin resistance. , 1983, Surgery.

[75]  R. DeFronzo,et al.  Epinephrine-induced insulin resistance in man. , 1980, The Journal of clinical investigation.

[76]  R. Rizza,et al.  Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. , 1980, The Journal of clinical investigation.

[77]  H. Berendsen,et al.  The α-helix dipole and the properties of proteins , 1978, Nature.

[78]  R. Steele,et al.  Measurement of size and turnover rate of body glucose pool by the isotope dilution method. , 1956, The American journal of physiology.

[79]  C. Cori,et al.  THE INFLUENCE OF INSULIN AND EPINEPHRINE ON GLYCOGEN FORMATION IN THE LIVER , 1929 .